The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Preferredfrequencyof GnRHagonistsUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialBased onOncotype DX,a score of 35will receivethis treatmentThis agentshould beinitiated withneratinib for thefirst 8 weeksThis drugclass are thebackbone ofHR+ diseaseThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate Duration of timepatients willtakeabemaciclib inearly stagediseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effect1%This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This treatmentmodality isalwayscombined withlumpectomysurgeryPreferredregimen forHR+ diseasefor frail/elderlypatientsThe onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score Preferredfrequencyof GnRHagonistsUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialBased onOncotype DX,a score of 35will receivethis treatmentThis agentshould beinitiated withneratinib for thefirst 8 weeksThis drugclass are thebackbone ofHR+ diseaseThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate Duration of timepatients willtakeabemaciclib inearly stagediseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effect1%This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This treatmentmodality isalwayscombined withlumpectomysurgeryPreferredregimen forHR+ diseasefor frail/elderlypatients

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. The only steroidal aromatase inhibitor in its drug class
  2. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  3. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  4. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  5. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  6. Patients with HER2+ disease continue targeted therapy for this duration
  7. This agent can be added to LN+ HER2+ disease given with trastuzumab
  8. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  9. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  10. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  11. Preferred frequency of GnRH agonists
  12. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  13. Based on Oncotype DX, a score of 35 will receive this treatment
  14. This agent should be initiated with neratinib for the first 8 weeks
  15. This drug class are the backbone of HR+ disease
  16. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  17. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  18. This subtype of breast cancer has the lowest relative 5-year survival rate
  19. Duration of time patients will take abemaciclib in early stage disease
  20. This agent can cause endometrial cancer, but has bone density protective effect
  21. 1%
  22. This should be monitored routinely every 3-4 months while receiving trastuzumab
  23. This treatment modality is always combined with lumpectomy surgery
  24. Preferred regimen for HR+ disease for frail/elderly patients